The Use of Brain Natriuretic Peptide in the Evaluation of Heart Failure in Geriatric Patients

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2023 May 13

PMID 37174904

Authors

Mihai Marinescu

Violeta Diana Oprea

Aurel Nechita

Dana Tutunaru

Luiza-Camelia Nechita

Aurelia Romila

Affiliations

Soon will be listed here.

Abstract

Heart failure is one of the main morbidity and mortality factors in the general population and especially in elderly patients. Thus, at the European level, the prevalence of heart failure is 1% in people under 55 years of age but increases to over 10% in people over 70 years of age. The particularities of the elderly patient, which make the management of heart failure difficult, are the presence of comorbidities, frailty, cognitive impairment and polypharmacy. However, elderly patients are under-represented in clinical trials on the diagnosis and treatment of heart failure. The need for complementary methods (biomarkers) for differential and early diagnosis of heart failure is becoming more and more evident, even in its subclinical stages. These methods need to have increased specificity and sensitivity and be widely available. Natriuretic peptides, in particular B-type natriuretic peptide (BNP) and its fraction NTproBNP, have gained an increasingly important role in the screening, diagnosis and treatment of heart failure in recent years.

Citing Articles

NT-proBNP for Heart Failure Screening in Primary Care in an Eastern European Country: What We Know and Proposed Steps.

Teleanu I, Mirsu-Paun A, Bejan C, Stanescu A Epidemiologia (Basel). 2025; 6(1.

PMID: 39846532 PMC: 11755574. DOI: 10.3390/epidemiologia6010002.

Care manager role for older multimorbid heart failure patients' needs in relation to psychological distress and quality of life: a cross-sectional study.

Gostoli S, Subach R, Guolo F, Bernardini F, Cammarata A, Gigante G Front Cardiovasc Med. 2024; 11:1432588.

PMID: 39411179 PMC: 11475247. DOI: 10.3389/fcvm.2024.1432588.

Role of dietary inflammatory index in the association of NT-proBNP with all-cause and cardiovascular mortality in NHANES 1999-2004.

Xie L, Liu J, Wang X, Liu B, Li J, Li J Sci Rep. 2024; 14(1):19978.

PMID: 39198638 PMC: 11358152. DOI: 10.1038/s41598-024-70506-3.

Association between natriuretic peptides and C-reactive protein with frailty in heart failure: a systematic review and meta-analysis.

Prokopidis K, Ishiguchi H, Jordan C, Irlik K, Nabrdalik K, Formiga F Aging Clin Exp Res. 2024; 36(1):57.

PMID: 38446241 PMC: 10917829. DOI: 10.1007/s40520-024-02713-x.

A Set of Possible Markers for Monitoring Heart Failure and Cognitive Impairment Associated: A Review of Literature from the Past 5 Years.

Pagano M, Corallo F, DAleo P, Duca A, Bramanti P, Bramanti A Biomolecules. 2024; 14(2).

PMID: 38397422 PMC: 10886491. DOI: 10.3390/biom14020185.

References

Dhaliwal A, Deswal A, Pritchett A, Aguilar D, Kar B, Souchek J . Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. J Card Fail. 2009; 15(4):293-9. DOI: 10.1016/j.cardfail.2008.11.007. View

Wang T, Larson M, Levy D, Leip E, Benjamin E, Wilson P . Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002; 90(3):254-8. DOI: 10.1016/s0002-9149(02)02464-5. View

Azad N, Lemay G . Management of chronic heart failure in the older population. J Geriatr Cardiol. 2015; 11(4):329-37. PMC: 4292097. DOI: 10.11909/j.issn.1671-5411.2014.04.008. View

Nielsen L, Svanegaard J, Klitgaard N, Egeblad H . N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Eur J Heart Fail. 2004; 6(1):63-70. DOI: 10.1016/j.ejheart.2003.10.003. View

Guerra F, Brambatti M, Matassini M, Capucci A . Current Therapeutic Options for Heart Failure in Elderly Patients. Biomed Res Int. 2017; 2017:1483873. PMC: 5705868. DOI: 10.1155/2017/1483873. View

Lainchbury J, Campbell E, Frampton C, Yandle T, Nicholls M, Richards A . Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003; 42(4):728-35. DOI: 10.1016/s0735-1097(03)00787-3. View

Leto L, Testa M, Feola M . Correlation between B-Type Natriuretic Peptide and Functional/Cognitive Parameters in Discharged Congestive Heart Failure Patients. Int J Endocrinol. 2015; 2015:239136. PMC: 4421025. DOI: 10.1155/2015/239136. View

Akita K, Kohno T, Kohsaka S, Shiraishi Y, Nagatomo Y, Izumi Y . Current use of guideline-based medical therapy in elderly patients admitted with acute heart failure with reduced ejection fraction and its impact on event-free survival. Int J Cardiol. 2017; 235:162-168. DOI: 10.1016/j.ijcard.2017.02.070. View

Blonde-Cynober F, Morineau G, Estrugo B, Fillie E, Aussel C, Vincent J . Diagnostic and prognostic value of brain natriuretic peptide (BNP) concentrations in very elderly heart disease patients: specific geriatric cut-off and impacts of age, gender, renal dysfunction, and nutritional status. Arch Gerontol Geriatr. 2010; 52(1):106-10. DOI: 10.1016/j.archger.2010.02.010. View

10.

Cherubini A, Oristrell J, Pla X, Ruggiero C, Ferretti R, Diestre G . The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med. 2011; 171(6):550-6. DOI: 10.1001/archinternmed.2011.31. View

11.

Passantino A, Guida P, Lagioia R, Ammirati E, Oliva F, Frigerio M . Predictors of Long-Term Mortality in Older Patients Hospitalized for Acutely Decompensated Heart Failure: Clinical Relevance of Natriuretic Peptides. J Am Geriatr Soc. 2016; 65(4):822-826. DOI: 10.1111/jgs.14561. View

12.

Van Veldhuisen D, Linssen G, Jaarsma T, van Gilst W, Hoes A, Tijssen J . B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013; 61(14):1498-506. DOI: 10.1016/j.jacc.2012.12.044. View

13.

Keyzer J, Hoffmann J, Ringoir L, Nabbe K, Widdershoven J, Pop V . Age- and gender-specific brain natriuretic peptide (BNP) reference ranges in primary care. Clin Chem Lab Med. 2014; 52(9):1341-6. DOI: 10.1515/cclm-2013-0791. View

14.

Taylor K, Verbakel J, Feakins B, Price C, Perera R, Bankhead C . Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: systematic review and meta-analysis. BMJ. 2018; 361:k1450. PMC: 5960954. DOI: 10.1136/bmj.k1450. View

15.

Borlaug B . Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2020; 17(9):559-573. DOI: 10.1038/s41569-020-0363-2. View

16.

Troughton R, Frampton C, Brunner-La Rocca H, Pfisterer M, Eurlings L, Erntell H . Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014; 35(23):1559-67. PMC: 4057643. DOI: 10.1093/eurheartj/ehu090. View

17.

Sayama H, Nakamura Y, Saito N, Kinoshita M . Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal?. Coron Artery Dis. 1999; 10(7):537-40. DOI: 10.1097/00019501-199910000-00016. View

18.

Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H . B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med. 2010; 170(6):507-14. DOI: 10.1001/archinternmed.2010.35. View

19.

. Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart Failure: A Health Technology Assessment. Ont Health Technol Assess Ser. 2021; 21(2):1-125. PMC: 8129637. View

20.

Barywani S, Ergatoudes C, Schaufelberger M, Petzold M, Fu M . Does the target dose of neurohormonal blockade matter for outcome in Systolic heart failure in octogenarians?. Int J Cardiol. 2015; 187:666-72. DOI: 10.1016/j.ijcard.2015.03.428. View